Pappas Capital In The News.

Check here for news about the latest breakthroughs, successes and innovations made possible by Pappas Capital, our portfolio companies and other partners.

May 24, 2017

New Pappas Capital Fund Makes First Investment

Research Triangle Park, NC — May 24, 2017 — Pappas Capital, a life science venture capital firm, announced today that its new fund, Pappas Ventures V, recently invested in OrphoMed, a clinical stage company that is developing best-in-class therapies for treatment of inadequately-controlled gastrointestinal disorders. The investment in OrphoMed is the first investment by the new Pappas Ventures fund.

Read Story

April 4, 2017

Sentien Biotechnologies, Inc. Announces $12 million Series A Financing

Cambridge, MA – April 4, 2017 – Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced today that it has closed a $12 million Series A investment round. The financing was co-led by Boehringer Ingelheim Venture Fund USA, Inc. (BIVF USA) and BioInnovation Capital, and joined by Chiesi Ventures, MBL Venture Capital Co., Ltd, and Mass Medical Angels. The Series A round will be used to fund initial clinical development of Sentien’s SBI- 101 for the treatment of acute kidney injury (AKI).

Read Story

March 30, 2017

Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment of Primary Ocular Melanoma

Cambridge, MA – March 30, 2017 – Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light-activated AU-011, an investigational, first-in-class targeted therapy in development for the treatment of ocular melanoma, a rare and life-threatening disease. Aura additionally announced today that the U.S. Food and Drug Administration (FDA) has granted AU-011 fast track designation for the treatment of primary ocular melanoma, also known as uveal or choroidal melanoma. This designation enables Aura to have more frequent interactions with the FDA throughout AU-011’s drug development process, as well as priority review of the New Drug Application (NDA). Fast track designation is granted to drugs that are for serious or life-threatening diseases and that the FDA believes demonstrate the potential to address unmet medical needs.

Read Story

February 6, 2017

Aura Biosciences Receives FDA Clearance of Investigational New Drug Application for Light-activated AU-011 for the Treatment of Ocular Melanoma

Cambridge, MA – February 6, 2017 – Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for the company’s lead program, light-activated AU-011 in ocular melanoma (OM). This active IND enables Aura to begin initial clinical testing of AU-011, a unique targeted therapy that could transform the primary treatment of patients with OM, a rare and life-threatening disease.

Read Story

January 31, 2017

Chondrial Therapeutics Secures Up to $22.6 Million in Series A Financing and Licenses Novel Technology for the Treatment of Friedreich’s Ataxia

Bala Cynwyd, PA – January 31, 2017 – Chondrial Therapeutics, Inc., an emerging biotechnology company focused on the treatment of rare mitochondrial diseases, announced today that it has secured up to $22.6 million in Series A financing led by Deerfield Management and has appointed Carole Ben-Maimon, MD, as the company’s president and chief executive officer. Concurrently, Chondrial announced the licensing of a novel investigational technology, CTI-1601, for the treatment of Friedreich’s Ataxia from Indiana University Research and Technology Corp. (IURTC) and Wake Forest University Health Sciences. CTI-1601 was invented by R. Mark Payne, MD, professor of Pediatric Cardiology at Indiana University School of Medicine and director of the Translational Research Training Program of Indiana Clinical Translational Sciences Institute.

Read Story

January 11, 2017

Pappas Capital and Wake Forest Innovations Announce First Investments by the Catalyst Fund

Winston-Salem, NC – January 11, 2017 – Pappas Capital and Wake Forest Innovations today announced the first technologies to receive initial investment from the Catalyst Fund, the $15 million technology development program established by Wake Forest Baptist Medical Center in October 2015.

Read Story

January 5, 2017

Amplyx Pharmaceuticals Appoints Ciara Kennedy, Ph.D., as President and Chief Executive Officer

San Diego, CA – January 5, 2017 – Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, today announced the appointments of Ciara Kennedy, Ph.D., to president and chief executive officer (CEO) and Karen Joy Shaw, Ph.D., to chief scientific officer (CSO). In conjunction with this announcement, the company’s former president and CEO, Mike Grey, has assumed the role of executive chairman of the Amplyx Board of Directors.

Read Story

November 16, 2016

Glycomine, Inc. Announces $12 Million Series A Financing

San Francisco, CA – November 16, 2016 – Glycomine, Inc. a biotechnology company developing a new generation of replacement therapies for rare diseases, today announced that it has raised $12 million in a Series A financing led by Sanderling Ventures and supported by Chiesi Ventures as well as existing high net worth individuals and patients. Glycomine will use the proceeds from this financing to complete IND enabling pre-clinical studies and initiate clinical studies of its substrate replacement therapy in patients with Congenital Disorder of Glycosylation Type Ia (CDG-Ia), and to accelerate discovery efforts towards an enzyme replacement therapy for N-glycanase deficiency (Ngly1).

Read Story

November 16, 2016

FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections

San Diego, CA – November 16, 2016 – Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development has granted orphan drug designation to APX001, the company’s lead drug candidate. APX001 has received orphan drug designation for four distinct indications: the treatment of invasive candidiasis, invasive aspergillosis, coccidioidomycosis, and rare mold infections caused by Scedosporium spp., Fusarium spp., and Mucorales fungi (including Mucor spp., and Rhizopus spp.).

Read Story

September 12, 2016

Amplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections

San Francisco, CA – September 12, 2016 – Amplyx Pharmaceuticals today announced the initiation of dosing in a Phase 1 clinical trial of APX001 in healthy volunteers. The randomized, double-blind, placebo-controlled, dose-escalation study will enroll approximately 80 healthy subjects. Intravenous infusion of APX001 will be administered as a single or multiple consecutive doses to healthy subjects. The objectives of this study include the evaluation of the safety, tolerability, and pharmacokinetics of APX001.

Read Story

February 9, 2016

Amplyx Pharmaceuticals Expands Management Team and Increases Its Series B Financing to $49.2 Million

San Diego, CA – February 9, 2016 – Amplyx Pharmaceuticals today announced that the company has expanded its management team with the appointments of Michael Hodges, M.D., as chief medical officer; Karen Shaw, Ph.D., as vice president of biology; and Elizabeth Gordon, Ph.D., as vice president of regulatory affairs. Also, the company announced that 3×5 Partners joined the Series B financing, bringing the total raised to $49.2 million. These developments further position the company to initiate the clinical development of APX001, Amplyx’s broad-spectrum antifungal agent for treatment of life threatening fungal infections.

Read Story

November 11, 2015

Amplyx Pharmaceuticals Secures $40.5 million in Series B Financing

San Diego, CA – November 11, 2015 – Amplyx Pharmaceuticals today announced the company has closed on a $40.5 million Series B financing. The round was led by RiverVest Venture Partners, and included investments by New Enterprise Associates, BioMed Ventures and individual investors. Amplyx will use the funding to advance the clinical development of APX001, the company’s broad-spectrum antifungal agent to treat life threatening fungal infections.

Read Story

October 14, 2015

Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)

Mataró, Barcelona, Spain – October 14, 2015 – Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces it has completed a Series A funding round of €19.4M ($21.7M). Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substantial syndicate of new investors including Kurma Partners, Roche Venture Fund, Idinvest Partners and Chiesi Ventures. Existing investors Caixa Capital Risc, the venture capital division of ‘la Caixa’ and HealthEquity also participated in the round.

Read Story

October 7, 2015

Wake Forest Baptist Medical Center Creates $15 Million Program to Develop Life Science Technologies

Winston-Salem, NC – October 7, 2015 – Wake Forest Baptist Medical Center today announced the creation of a Technology Development Program, a $15 million program to develop the ideas, discoveries and inventions of the faculty and staff of the Medical Center into life science technologies having the potential to benefit patients in the community and worldwide.

The new program is in partnership with leading life science investment firm Pappas Capital, in Durham. Funds will be managed by Pappas in collaboration with Wake Forest Innovations to advance clinically important life science technologies for licensing to established companies or startups.

Read Story

September 24, 2015

Intarcia Therapeutics Announces Acquisition of Phoundry Pharmaceuticals

Boston, MA – September 24, 2015 – Intarcia Therapeutics, Inc. today announced the acquisition of Phoundry Pharmaceuticals, Inc., a privately held biotechnology company based in Research Triangle Park, North Carolina. Founded in 2015 after six years of work as part of the Enteroendocrine Discovery Performance Unit of GlaxoSmithKline, Phoundry Pharmaceuticals has created a portfolio of optimized peptides in various therapeutic categories, most notably diabetes and obesity.

Phoundry enhances Intarcia’s internal efforts to build upon the differentiated clinical success of its Phase 3 investigational therapy, ITCA 650, the first injection-free GLP-1 therapy with the potential to deliver up to a full year of treatment from a single placement.

Read Story

August 18, 2015

New Peptide Company Phoundry Closes Seed Funding

Research Triangle Park, NC – August 18, 2015 – Phoundry Pharmaceuticals, Inc., an RTP, North Carolinabased company focusing on the discovery of peptide therapeutics, announced today that it has successfully completed its first seed financing, putting it in position to advance its discovery and partnering plans.

Read Story

March 5, 2015

Chiesi Ventures invests in Aura Bioscience

Cambridge, MA – March 5, 2015 – Aura Biosciences, a biotech company developing highly tumor-targeted breakthrough therapies for rare cancers, has secured a $21M Series B round of funding. The financing was led by Advent Life Sciences, with participation from new investors, Chiesi Ventures, Ysios Capital, and Alexandria Venture Investments. Existing investors, including LI-COR Biosciences…

Read Story